The headline numbers are stark. Across the pooled observational studies, adults and children with an ADHD diagnosis had a 70 percent higher rate of death from any cause than people without the diagnosis. The excess risk was not confined to a single category of death. The rate of death by suicide was 90 percent higher among people with ADHD, the rate of death from injuries, whether intentional or accidental, was 55 percent higher, and the rate of death from natural causes was 27 percent higher. In some of the included studies, participants were followed for more than two decades, allowing the researchers to track mortality patterns across a substantial portion of the life course.

Senior author Professor Joshua Stott of UCL Psychology and Language Sciences said the findings build directly on earlier work from his team. We have previously found that people with ADHD have reduced life expectancies, so here we are adding to our understanding of what drives this very concerning statistic, he said. We found that people with ADHD face an increased risk not only of death by suicide and injury, but also of deaths by natural causes, adding to evidence that health inequalities faced by people with ADHD are broad and wide-ranging.

Stott was careful to stress that the diagnosis itself is not an inevitable path to early death. ADHD is not by definition a life-limiting condition, he said, as the right support and treatment can help people with ADHD to live long and healthy lives. He argued that the results underscore the importance of ensuring that everyone who may have ADHD has access to accurate diagnosis and treatment. While diagnosis rates have risen in recent years, he noted, they may still lag behind actual prevalence, particularly among older adults, precisely the group in which mortality risk may be most pertinent.

What might explain the elevated mortality? The researchers point to a converging set of mechanisms. People with ADHD are more likely to experience mental health problems and face challenges with emotional regulation, impulse control and risk-taking, all of which can elevate the likelihood of fatal outcomes such as suicide or accidental injury. They also experience more societal exclusion, disadvantage and stigma, factors that independently shape health trajectories. Unintentional injury deaths, such as road traffic fatalities, may additionally be linked to differences in attention, a core feature of the condition.

Natural-cause mortality, the 27 percent excess in deaths from physical disease rather than external events, fits a broader picture emerging from the same research group. Previous studies led by the UCL co-authors found that people with ADHD experience higher rates of physical health conditions such as cardiovascular disease, metabolic disorders, diabetes and cancer. Mortality from natural causes may be linked to health risk behaviours such as smoking or alcohol use. People with ADHD may also experience challenges with engagement and access to health care, and with adherence to medical treatment, meaning that even when conditions are treatable, the treatment may not reach the people who need it.

Against that backdrop, the most striking finding of the new analysis is the apparent protective signal associated with medication. Among people with ADHD, those who took ADHD medication appeared to have a 25 percent lower mortality risk than those who did not. First author Lucy Corrigan of the University of Liverpool said the results provide early evidence to suggest that medication may play an important role in supporting the health of people with ADHD, but she was quick to add that this is based on a small number of studies and further research is needed to clarify this link. Medication is just part of the story, she said; many people with ADHD benefit from comprehensive, long-term treatment and support.

Senior author Dr Amber John, also of UCL Psychology and Language Sciences and the University of Liverpool, framed the findings as an argument for equity. Many people with ADHD face challenges throughout their lives, she said, so equitable access to evidence-based assessment and treatment is vital to ensure they can live long, healthy lives. The message from the research team is that the mortality gap is not an intrinsic feature of the condition but a reflection of modifiable risks, from untreated symptoms to barriers in health systems.

The authors themselves urge caution in how strongly the results should be read. There were broad differences between the studies included in their analysis, and while they did generally find that ADHD is linked to higher mortality, the individual studies produced very disparate results as to the magnitude of the effect. The medication finding deserves particular restraint in interpretation, the researchers say, because it was based on only three of the 19 included studies. More fundamentally, because all of the studies in the review were observational, it is not possible to infer causality. It remains possible, for example, that people who receive and adhere to medication differ from those who do not in ways that also influence mortality, such as engagement with health services more broadly.

Even with those caveats, the study adds considerable weight to a growing body of evidence that ADHD is a serious public health issue with consequences measured in years of life. Previous research from the same UCL co-authors estimated an apparent reduction in life expectancy for men with diagnosed ADHD of between 4.5 and 9 years, and between 6.5 and 11 years for women. Separate UCL work has suggested that ADHD may be underdiagnosed in adults across England, and that childhood ADHD is linked to midlife physical health problems. Taken together, the picture is of a condition whose long-term health impact has been systematically underestimated, and whose treatment, if the early medication signal holds up in further research, could offer one of the clearest available levers for reducing that impact.

Subject of Research: Mortality risk and medication effects in ADHD

Article Title: ADHD linked to higher mortality but medication may help

Article References: ADHD linked to higher mortality but medication may help. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ADHD, mortality, meta-analysis, medication, suicide risk, injury deaths, natural-cause mortality, JAMA Network Open, UCL, University of Liverpool, mental health, life expectancy

The research team surveyed 1,185 adults based in the United States, asking them how they felt about the use of AI within secure medical portals, the encrypted messaging environments where patients routinely contact their care teams with questions, requests, and concerns. These portals have become a central artery of modern outpatient care, and health systems have increasingly looked to AI tools to help manage the sheer volume of messages that flows through them. The Columbia study examined a specific and practical question at the heart of that trend: how quickly do patients want AI to act, and how much human oversight do they demand before an AI-assisted response reaches them?

The answer, the researchers found, depends heavily on what kind of help a patient is seeking. For logistical requests, a majority of respondents, 57 percent, said they preferred fast AI-generated responses. These are the routine transactions of clinical administration, such as appointment scheduling and prescription refills, where the information needed is often factual, standardized, and unlikely to require nuanced medical judgment. In these lower-stakes situations, patients appeared willing to trade the involvement of a clinician for the convenience of an immediate, automated reply.

Medical questions told a very different story. Two-thirds of participants said they would rather wait up to 48 hours for a doctor or nurse to review and edit an AI response to a medical question than receive an unreviewed AI answer right away. That preference for delayed but human-verified information represents a striking rebuke to the assumption that patients value speed above all else. When the content of a message touches on diagnosis, treatment, or clinical guidance, the survey suggests, people want the assurance that a trained professional has read the words before they do, even if that assurance costs them two days of waiting.

The study’s title, Public Perceptions of Timeliness for AI Use and Human Oversight, captures this central tension between immediacy and verification. Lead author Natalie Benda, PhD, an assistant professor at Columbia Nursing, said the results confirmed what the team had suspected but could now support with data. When people have a medical question, she noted, they want to hear from their doctor, not AI, even if AI may give an immediate answer. Her co-authors included Uday Suresh, Megan E. Salwei, and Laurie Lovett Novak of Vanderbilt University Medical Center; Afra Shamnath and Meghan Reading Turchioe of Columbia University School of Nursing; Isabella Buitron of the Columbia University Mailman School of Public Health; and Xuhai (Orson) Xu of Columbia’s Department of Biomedical Informatics.

Mental health support emerged as a particularly revealing test case in the survey. Participants were presented with three options for obtaining mental health care, each differing in the balance between human involvement and availability. A licensed human therapist with a three-month wait drew the strongest support, at 64 percent. A therapist-monitored AI chatbot available within one month was acceptable to 50 percent of respondents. An AI-only chatbot available immediately, the fastest and most automated option, was the least popular, at 44 percent. The gradient is instructive: each step that reduced human oversight or increased automation corresponded to a measurable drop in acceptance, even as each step also shortened the wait for care.

That pattern matters because mental health care is one of the areas where AI chatbots are being deployed most aggressively, often justified by the severe shortage of therapists and the long delays patients face in securing appointments. The survey data suggest that patients themselves are acutely aware of this trade-off. Many would apparently rather endure a three-month wait for a licensed human therapist than receive instant support from a system with no human involvement at all. At the same time, the fact that half of respondents found a therapist-monitored chatbot acceptable indicates a meaningful openness to hybrid models, in which AI handles day-to-day interaction while a clinician supervises the overall course of care.

The study also revealed that attitudes toward AI in medical settings are not uniform across the population. Benda noted that people’s opinions differed across characteristics such as race, health literacy, gender, and experiences of discrimination in medical settings. One of the most notable findings was that individuals who reported having been discriminated against in a medical setting were more open to AI responses to medical questions. That counterintuitive result complicates any simple narrative about technology acceptance. For some patients, the prospect of an AI-mediated interaction may feel less fraught than an encounter with a health system in which they have previously felt mistreated, suggesting that the drivers of trust in AI are entangled with broader experiences of inequity in care.

The authors argue that these findings carry a direct implication for how health systems design and deploy AI tools: patients should be allowed to make decisions about how and when AI is used in their medical care. Rather than imposing a single policy across all message types, the study suggests, portals and clinics may be more successful if they let patients choose, reserving rapid AI responses for administrative tasks while routing medical questions through clinician review. The data indicate that patients may be receptive to AI in lower-stakes situations but continue to expect clinician involvement for higher-stakes medical decisions and guidance. Offering that choice could preserve the efficiency gains that motivate AI adoption while respecting the trust conditions on which patient acceptance depends.

As health systems weigh investments in AI-powered messaging, triage, and patient communication, the Columbia survey provides a quantitative anchor for those decisions. It quantifies the willingness of a large sample of U.S. adults to wait for human review, the tasks for which they will accept automation, and the demographic fault lines along which acceptance varies. The message from the 1,185 respondents is consistent and pragmatic: AI can handle the scheduling and the refills, but when the question turns to health and the answer carries clinical weight, patients want a doctor or nurse to read it first, even if that means waiting an extra 48 hours.

Subject of Research: Public perceptions of AI-generated medical responses and human oversight in patient portals

Article Title: Most patients won't endorse AI medical responses without a clinician's review, Columbia Nursing study in JAMA Network Open finds

Article References: Most patients won't endorse AI medical responses without a clinician's review, Columbia Nursing study in JAMA Network Open finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, patient portals, clinician oversight, JAMA Network Open, Columbia University School of Nursing, health care AI, patient trust, mental health chatbots, medical messaging, health literacy, health care discrimination, survey research

Colic, typically defined as excessive, inconsolable crying in an otherwise healthy infant, affects a substantial share of newborns and remains one of the most frequent reasons parents seek medical advice in the first months of life. Eczema, an inflammatory skin condition, is equally common and is widely recognized as an early marker of atopic disease. In the new study, 26 percent of the infants examined had colic, and 5 percent had both colic and eczema. That combination matters, the researchers argue, because previous work by the same team showed that babies with colic go on to have higher rates of atopic conditions later in childhood, including asthma, seasonal rhinitis, and food allergies. Infants who display both colic and eczema in infancy may represent the group at highest risk for allergic manifestations as they grow older.

Corresponding author Jenifer Lightdale, associate chief of the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital and professor of pediatrics at Harvard Medical School, framed the study as a departure from earlier approaches. Prior research on diet and colic has generally focused on interventions after birth, testing whether dietary changes in breastfeeding mothers or modifications of infant formula could ease symptoms once they were already present. The new investigation instead asked a more fundamental question: whether the dietary habits a woman maintains during pregnancy are associated with the risk that her baby will develop colic in the first place, and in particular the combined presentation of colic and eczema. According to Lightdale, the study is the first to examine how prenatal diet may influence this combination of infant conditions.

The evidence base for the analysis comes from Project Viva, a long-running prebirth cohort study that recruited more than 1,300 pregnant women from prenatal clinics in Eastern Massachusetts between April 1999 and November 2002. During pregnancy, participants completed regular food questionnaires, allowing the researchers to characterize their diets in detail. The team scored each participant’s diet using two established instruments: the Mediterranean Diet Score, or MDS, and the Dietary Inflammation Index, or DII. A high MDS score reflected a more healthful eating pattern, characterized by high intake of fruits, vegetables, whole grains, legumes, and healthy fats, along with moderate intake of dairy and lean proteins. A high DII score, by contrast, signaled a less healthful, more pro-inflammatory diet, with high intake of red or processed meats, sugar-sweetened beverages, sodium, and refined grains.

The questionnaires also captured the participants’ consumption of foods commonly considered allergenic, including peanuts, peanut butter, and other nuts; finfish and shellfish; and eggs and dairy. This allowed the researchers to move beyond overall dietary patterns and ask whether specific food groups were individually associated with infant outcomes. The design is observational, meaning it identifies associations rather than proving that dietary changes directly cause differences in infant health, but the cohort’s size, prospective structure, and use of validated dietary scoring instruments give the findings considerable weight in a field where rigorous prenatal evidence has been scarce.

The results were striking in their consistency. Each additional point on the Mediterranean Diet Score was associated with a 15 percent reduction in the risk of having a baby with both colic and eczema, while each higher point on the Dietary Inflammation Index was associated with a 34 percent increase in that risk. In other words, the two dietary measures pointed in opposite directions, and both pointed toward the same conclusion: an anti-inflammatory, nutrient-dense dietary pattern during pregnancy was linked to a lower likelihood of the combined infant conditions, whereas a pro-inflammatory pattern was linked to a higher likelihood. The researchers also calculated that all of the associations they observed were strongest among infants whose mothers had a history of allergic conditions, suggesting that prenatal diet may be particularly consequential for children already predisposed to atopic disease.

Among the individual food groups examined, one stood out. For each weekly serving of seafood a pregnant woman consumed, her infant had a 25 percent lower chance of having both colic and eczema. Seafood is a rich source of long-chain omega-3 fatty acids, vitamin D, and other nutrients that have been implicated in immune development and inflammatory regulation, although the study was not designed to isolate which specific components of seafood might be responsible. Notably, the other typical allergenic foods the researchers assessed, including dairy, eggs, and nuts, were not related to the risk of having a baby with colic and eczema. That finding may reassure pregnant women who have worried that eating common allergens during pregnancy could sensitize their babies, at least with respect to these particular infant outcomes.

First author Emily Oken, president of the Harvard Pilgrim Health Care Institute and professor in the Department of Nutrition at Harvard Chan School, emphasized that the findings offer pregnant women a practical and achievable target. She noted that mothers wish to do all they can for their babies, but that financial and structural barriers often stand in the way of accessing healthy nutrition. Oken expressed hope that the study will be useful not only to individuals and families but also to the programs and services that support women’s health and nutrition, citing federal programs such as WIC and SNAP as well as initiatives administered by health plans and health systems, including food is medicine programs that integrate nutritional support into medical care. The framing reflects a growing recognition in public health that dietary guidance during pregnancy is only as effective as the access that accompanies it.

The study was supported by the National Institutes of Health under grant R01HD034568 and by a gift from an anonymous donor to Harvard Chan School. The authors disclosed a range of financial relationships outside the submitted work, including research grants and consulting arrangements with academic funders and industry partners, which are documented in the published paper. As an observational study, the research cannot establish causation, and residual differences between women who eat Mediterranean-style diets and those who do not, such as other lifestyle or socioeconomic factors, could contribute to the observed associations. Even so, the consistency of the results across two independent dietary scores, the dose-response pattern linking each additional seafood serving to lower risk, and the amplification of the associations among children of mothers with allergic histories together make a compelling case that prenatal diet deserves a place in conversations about infant colic and eczema. For expectant parents, the message is straightforward: a balanced, Mediterranean-style diet rich in fruits, vegetables, whole grains, legumes, healthy fats, and regular servings of seafood may offer benefits that extend well beyond pregnancy itself, potentially shaping an infant’s earliest experiences of comfort, skin health, and long-term allergy risk.

Subject of Research: Association between maternal prenatal diet quality and infant colic and eczema risk

Article Title: Healthy diet during pregnancy associated with reduced risk of infant colic, eczema

Article References: Healthy diet during pregnancy associated with reduced risk of infant colic, eczema. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prenatal diet, Mediterranean diet, colic, eczema, seafood, infant health, allergy risk, Project Viva, Dietary Inflammation Index, pregnancy nutrition, atopic disease, JAMA Network Open

Percutaneous coronary intervention, commonly known as PCI, is the definitive emergency treatment for many heart attacks. The procedure involves threading a catheter, usually through an artery in the wrist or groin, up to the blocked coronary artery that is starving heart muscle of oxygen. Cardiologists then inflate a small balloon and typically deploy a stent, a tiny metal scaffold, to prop the vessel open and restore blood flow. The intervention is exquisitely time-sensitive: the longer the artery stays occluded, the more heart muscle dies, and the greater the risk of fatal arrhythmias, heart failure, and death. That time dependence is why emergency medicine guidelines emphasize rapid door-to-balloon intervals, and why the geographic distance between a patient and a PCI-capable hospital can be a matter of life and death. Establishing a PCI program is also expensive and demanding, requiring specialized catheterization suites, imaging equipment, and a round-the-clock team of interventional cardiologists, nurses, and technicians.

The research team, led by Yu-Chu Shen of the Naval Postgraduate School and the National Bureau of Economic Research and Renee Y. Hsia, professor of emergency medicine at UCSF, took advantage of a natural experiment embedded in California’s health care landscape. Between 2011 and 2022, various hospitals across the state opened new PCI-capable facilities at different times and in different places. The researchers identified 590,282 hospitalizations for acute myocardial infarction, the medical term for heart attack, and asked a deceptively simple question: what happened to patients in a community after a PCI-capable facility opened within a 30-minute drive? Crucially, they separated communities into two groups based on their starting point, comparing places that had never had timely PCI access with places that already had a capable hospital within the same 30-minute radius.

The contrast between the two groups was stark. In communities that previously lacked timely access, the opening of a new facility was associated with a 53 percent relative increase in the likelihood that a heart attack patient would be admitted to a hospital capable of performing PCI, and a 16 percent increase in the likelihood that the patient would actually receive the procedure. Those changes in treatment were accompanied by substantial changes in survival: thirty-day mortality among heart attack patients fell by 20 percent, and one-year mortality fell by 15 percent. In communities where PCI was already available within 30 minutes, by contrast, the opening of yet another facility increased admission to a PCI-capable hospital by only 2 percent and use of the procedure by only 3 percent, and the study detected no significant change in mortality at either time horizon.

The pattern reveals a fundamental asymmetry in how health care capacity behaves. Where a service is absent, adding it changes clinical behavior profoundly, rerouting patients who would otherwise have received less definitive therapy toward the lifesaving procedure. Where the service already exists, an additional facility mostly reshuffles existing patterns of care, drawing some patients from one capable hospital to another without meaningfully changing who gets treated or how quickly. In economic terms, the marginal benefit of the first facility within reach of a population is enormous, while the marginal benefit of the second or third approaches zero. Hsia illustrated the point with a deliberately mundane analogy: adding another gas station to a neighborhood that already has five may make refueling slightly more convenient, but building one where residents previously had to drive 30 miles meets a genuine need. With emergency cardiac care, she noted, filling that kind of gap can save lives.

The geographic dimension of the problem was most acute in rural California. Among the 52,756 heart attack patients in the study who came from rural communities, 81 percent lived in places without a PCI-capable facility within a 30-minute drive at the beginning of the study period. That figure captures a structural vulnerability of rural health systems: specialized services that require high volumes, expensive equipment, and scarce subspecialists tend to concentrate in urban and suburban population centers, leaving rural patients with long transport times precisely when minutes matter most. For these communities, the study’s findings suggest that even a single new PCI-capable facility could produce mortality reductions on the order of 15 to 20 percent, an effect size that few other health system interventions can match.

The new analysis builds directly on earlier work by Hsia and colleagues, which had examined the supply side of the same question. That previous study found that the total number of PCI procedures performed in a community rose by 7.5 percent after a new facility opened, but the increase was far from uniform: it approached 20 percent in communities that had previously lacked timely access, compared with roughly 8 percent in communities where PCI was already available. In other words, new capacity reliably generates more procedures, but the increase partly reflects redistribution of existing patients among competing hospitals rather than genuinely new treatment for people who would otherwise have gone without. The current study extends that logic to the outcome that ultimately matters, asking whether the additional procedures improved survival, and finding that the answer depends entirely on whether the capacity filled a gap or duplicated an existing service.

That distinction carries weight because of how decisions about specialized services are actually made in the American health system. The researchers point out that the placement of new facilities is frequently driven by market demand, expected procedure volumes, and hospitals’ anticipated return on investment rather than by systematic assessments of population need. A hospital system may find it financially attractive to open a second PCI laboratory in a well-served suburban corridor where it can capture market share from a competitor, while no institution finds it profitable to establish one in a rural county with a small and dispersed population. The result, the study implies, is a systematic misallocation: capital flows toward communities where the clinical benefit of additional capacity is smallest, while the places where a new facility would save the most lives remain unserved. Market forces, in this domain, do not naturally point resources toward maximal population health benefit.

For policymakers, the findings suggest a concrete principle for allocating scarce health care infrastructure investment: measure access before adding capacity. Rather than asking whether a region can support more specialized services, planners could ask whether residents can already reach those services within the critical treatment window, and direct new facilities and support programs toward the communities that cannot. Hsia framed the principle as a question of priorities. When millions of dollars are invested in specialized health care infrastructure, she argued, the question should not simply be whether more services can be provided, but where those services will do the most good. Expanding access, she said, needs to be done wisely. The study’s mortality figures give that advice quantitative teeth: the same investment that yields no measurable survival benefit in a saturated market can cut heart attack deaths by a fifth in a community that has been going without.

The research also carries a broader lesson for how the public and the press evaluate health care expansion announcements. A ribbon-cutting for a new specialty facility is often reported as an unambiguous improvement in local care, and in a community with no existing access, that framing is accurate. But the California data show that in well-served areas, additional capacity may increase treatment rates only marginally while leaving survival untouched, meaning the true value of such investments is far smaller than the rhetoric suggests. As health systems, insurers, and governments confront rising costs and finite resources, the study offers a reminder that in medicine, as in geography, position matters. The lifesaving power of a procedure like PCI is not just a property of the catheter and the stent; it is a property of the distance between the patient and the door.

Subject of Research: Geographic access to percutaneous coronary intervention facilities and heart attack survival outcomes

Article Title: When it comes to health care access, more isn't always better

Article References: When it comes to health care access, more isn't always better. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: heart attack, percutaneous coronary intervention, health care access, rural health, mortality, emergency care, health policy, hospital capacity, California, JAMA Network Open, cardiovascular disease, health care infrastructure

The study, published in JAMA Network Open by researchers at Penn State College of Medicine, examined the de-identified health records of 12.6 million American women between the ages of 40 and 64 who received routine mammograms between 2008 and 2019. The team, led by first author Dong-Won Kang of Ajou University in Korea and senior author Chan Shen, Howard E. Morgan Professor in Surgery and professor of public health sciences at Penn State College of Medicine, set out to disentangle the effects of two legislative approaches that prior research had often bundled together. The first approach, notification laws, requires mammography facilities to tell women when a radiologist identifies dense breast tissue on their scan. The second, insurance coverage mandates, requires health insurers to pay for supplemental follow-up tests such as breast ultrasound and magnetic resonance imaging.

The central finding is striking in its asymmetry. Both forms of legislation independently produced modest increases in supplemental imaging, but insurance coverage mandates had nearly four times the impact of notification laws alone. When states required insurers to cover the cost of supplemental ultrasound, use of the procedure rose by roughly 47 additional examinations per 1,000 women screened. Notification laws, by comparison, were associated with about 13 additional ultrasounds per 1,000 women. In other words, telling a woman she has dense breasts opens a door, but paying for what lies beyond that door is what gets most patients through it.

Understanding why this distinction matters requires a brief look at the biology of breast density. Breasts are composed of three tissue types: fibrous connective tissue, glandular tissue and fatty tissue. Women with dense breasts carry proportionally more fibrous and glandular tissue, which appears white on a mammogram. Tumors and other abnormal changes also appear white, which means dense tissue can effectively camouflage malignancies against a bright background, a phenomenon radiologists describe as masking. Compounding the problem, dense tissue cannot be felt during a physical examination and can only be identified through medical imaging, which is precisely why so many women remain unaware of their own density status without legislative intervention.

The legislative landscape that has emerged is far from uniform, and that variation became a key analytical lever for the Penn State team. As Shen explained, some states require notifications to be sent only to women with dense breasts, while others send a general notice to everyone undergoing mammography. Some states include information about supplemental screening options in their notification letters, and others do not. A smaller number of states have gone further with insurance mandates, some covering ultrasound only, some covering MRI only, and some covering both. Pennsylvania offers a concrete example of the progression: the state passed its Breast Density Notification Act in 2013, requiring facilities to inform patients of density findings, and beginning in 2022 it required all health insurers to cover breast ultrasounds and MRIs for women with high-risk conditions, including dense breast tissue. At the federal level, the Food and Drug Administration began requiring mammography facilities to inform all patients about their breast density in 2024, but no federal law mandates coverage for supplemental testing.

Working within the MarketScan national insurance claims database, the researchers analyzed records from women who had continuous insurance coverage for at least six months after their screening mammogram. The population distribution across legislative environments revealed how uneven adoption has been: 21 percent of women in the sample lived in states with dense breast notification laws, and nearly 60 percent of those lived in states whose notifications included information about supplemental screening. Only 7 percent lived in states requiring insurance coverage for ultrasounds, and just 3 percent lived in states requiring MRI coverage. This patchwork allowed the investigators to compare outcomes across policy regimes while controlling for the confounding that had limited earlier studies.

The granularity of the findings extended beyond the headline contrast. Within states that had notification laws, ultrasound uptake was higher when the laws required notices to mention supplemental screening explicitly, and when notices were targeted specifically to women with dense breasts rather than sent to all screening patients. Notification laws were also associated with a small increase in MRI use, on the order of one additional examination per 1,000 women screened. Insurance mandates for MRI, however, produced no statistically significant change in MRI utilization, a result Shen attributed to the fact that patients with a personal or family history of breast cancer were already much more likely to receive MRI imaging, making this modality less responsive to legislative nudges. She also pointed to cost and logistics that the study did not measure directly: MRIs are generally more expensive tests, and there are fewer facilities offering them, which may create accessibility barriers that dampen demand regardless of what insurers are required to pay.

Perhaps the most sobering statistic in the study concerns the overall baseline. Across the entire sample, only 9 percent of women received supplemental ultrasound imaging and a mere 0.6 percent received supplemental MRI within six months of a screening mammogram, despite the fact that more than 40 percent of middle-age and older women have dense breasts. Even in the most supportive policy environments, supplemental imaging remains the exception rather than the rule. The analysis also identified demographic gradients in follow-up care: older women, women living in rural communities, and those with other health conditions were all less likely to obtain supplemental screening, suggesting that geography, comorbidity and age compound the financial barriers that insurance mandates are designed to remove.

Shen was careful to frame the results without overstatement. Not everyone with dense breasts needs supplemental screening, she noted, but a woman first needs to know whether she has dense breasts before she can make that decision in consultation with her healthcare provider. The findings, she argued, point to logistical and geographical barriers that influence whether women pursue follow-up screening, including cost, the availability of imaging facilities and patient preference. While more research is needed, the study offers a roadmap for policymakers seeking to maximize the public health impact of dense breast legislation: notification requirements raise awareness, but coverage requirements convert awareness into action, and the two work best in combination with attention to the practical obstacles that keep rural and older patients away from imaging centers.

For a field in which supplemental screening policy is still being written state by state, the study provides the first large nationwide evidence that the design details of legislation matter enormously. A notification letter that mentions supplemental screening reaches more women than a generic notice, and an insurance mandate reaches roughly four times as many as any letter alone. With the FDA’s federal notification requirement now in effect but coverage decisions left to states and insurers, the Penn State analysis suggests that the next frontier in dense breast policy is not information but access, ensuring that the women who learn about their density can actually afford and reach the tests that might catch what a mammogram missed.

Subject of Research: The effect of dense breast notification laws and insurance coverage mandates on supplemental breast imaging use after mammography

Article Title: Breast density laws linked to higher ultrasound use after mammography

Article References: Breast density laws linked to higher ultrasound use after mammography. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast density, mammography, supplemental screening, breast ultrasound, breast MRI, insurance mandates, notification laws, breast cancer screening, health policy, JAMA Network Open, Penn State College of Medicine, screening disparities

The survey asked participants whether they had ever used social media, how old they were when they first used it, and whether they currently held a social media account. Alongside these questions about access and timing, the adolescents answered standardized questions designed to measure symptoms of anxiety and depression. The resulting picture was striking: 70 percent of the youngsters had used social media at some point, roughly half already had an account of their own, and the average age at first use was just 11 years old. Those numbers alone illustrate how deeply embedded social media already is in the lives of Australian children well before they reach the minimum age threshold set by the new legislation.

What distinguished this study from much of the existing literature was its focus on the timing of first exposure rather than the binary question of access. Chief investigator Associate Professor Susanne Schweizer said the team was surprised that the age at which children first started using social media appeared to matter more for their mental health than simply whether they had an account. In her view, the result suggests that delaying children’s first exposure may be a promising policy direction, especially if the delay is paired with training in good digital hygiene and digital citizenship. That framing reframes the debate: rather than asking only whether children should be on social media, it asks when they should begin, and what skills they should carry with them when they do.

Lead author Anna Bilston, a UNSW PhD candidate, argued that governments may need to think beyond access restrictions if they genuinely want to protect young people’s mental health. If the goal is protection, she said, the relevant questions concern not only whether young people can access social media but also how young they are when they first start using it. This distinction carries technical weight for policy design. An age-based ban, such as Australia’s under-16 restriction, targets access directly, but the study’s findings imply that the developmental timing of first use is an independent variable, one that a pure access restriction may not fully capture if children continue to encounter social media informally or through peers at younger ages.

The behavioral intentions reported by the adolescents add a sobering dimension to the policy picture. Only a quarter of the 10-to-15-year-olds said they intended to stop using social media following the ban. Just over a third, 34 percent, said they still intended to use it without an account, while a similar proportion, 35 percent, said they intended to find a way around the restrictions in order to continue using their existing accounts. Taken together, more than three quarters of the surveyed young people planned to continue using social media in some form despite the new law, a compliance challenge that the researchers themselves did not shy away from describing.

Schweizer noted that most young people who intend to keep using social media expect to find ways around the restrictions rather than simply waiting until they turn 16. This expectation of circumvention is a well-recognized problem in behavioral policy: restrictions that are easy to evade, whether through borrowed accounts, false age declarations, or alternative platforms, can shift behavior underground without reducing exposure. Yet the researchers were careful not to conclude that the ban has failed. Schweizer suggested that for some families the ban likely helped start conversations about the mental health risks of social media between parents and children, between teachers and students, and among young people themselves. In behavioral science, she observed, attitudes often change before behavior, so it remains too early to judge whether the policy has been successful.

The researchers argue that protecting young people’s mental health will require more than restricting access alone. Parents and educators, they contend, have an equally important role in helping young people develop healthy digital habits and in delaying their first use of social media. This positions the Australian ban not as a complete solution but as one instrument within a broader preventive framework, one in which families and schools actively shape the developmental trajectory of digital engagement. The emphasis on delaying first use, rather than merely blocking platforms, aligns with a growing interest in prevention science, where early developmental windows are treated as critical intervention points for later mental health outcomes.

A companion study by the same research group adds nuance to the question of what kinds of social interaction actually serve young people well. That study followed older teenagers and young adults over time, asking them to record whether their social interactions took place online or in person, and how those interactions made them feel. The results showed that face-to-face interactions generally left young people feeling more positive and more included than online interactions. However, socially sensitive young people appeared to find online interactions easier. Schweizer offered a possible explanation: these young people may experience a short-term benefit from online interactions because they have more time to think about their responses. Over time, though, it is face-to-face interactions that appear to sustain positive relationships, although she emphasized that this interpretation remains speculative at this stage.

The companion findings resist a simple helpful-or-harmful framing of adolescent online activity. As Schweizer put it, young people’s online activity is more complex than that binary suggests. Some online interactions may play an important role, particularly for socially sensitive young people, even though face-to-face interactions remain important overall. For policy makers, this complexity matters. A blanket restriction that eliminates online social contact could remove a genuinely useful channel for some adolescents, even as the main study’s results point to the risks of early first exposure. The combined message is that interventions should be calibrated to developmental stage and individual differences rather than applied as a single blunt instrument.

The results published today represent the first stage of a larger Australian study, registered with a protocol published in BMJ Open, that will follow young people before and after the social media ban. The researchers will continue tracking participants over the next year to see whether the policy changes behavior, attitudes, mental health, and exposure to online harms. Schweizer described the situation as one of the first opportunities anywhere in the world to understand what happens when a policy of this kind is introduced, noting that the team now needs to follow these young people over time to see whether teenagers benefit from the new restrictions and what could be improved. With the ban already in force and the cohort assembled, the study stands to generate some of the most direct evidence yet on whether delaying and restricting social media can meaningfully shift adolescent mental health outcomes, and whether the attitudes recorded on the eve of the ban translate into lasting behavioral change.

Subject of Research: The relationship between age of first social media use and anxiety and depression symptoms in Australian adolescents surveyed before the national under-16 social media ban.

Article Title: Starting social media younger linked to anxiety, depression in teens

Article References: Starting social media younger linked to anxiety, depression in teens. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: social media, adolescent mental health, anxiety, depression, Australia social media ban, UNSW Sydney, JAMA Network Open, digital hygiene, age of first use, survey research, policy evaluation, face-to-face interaction

The research is notable not only for its conclusions but for its extraordinary time horizon. Rather than a snapshot survey asking people how they slept last night, the study followed participants from young adulthood into middle age for nearly 35 years, repeatedly tracking their cannabis use across decades of their lives. In middle age, participants wore a wrist-based sleep monitor for a full week and completed sleep surveys, allowing the scientists to compare objective measures of sleep — the kind captured by sensors rather than self-assessment — with participants’ own perceptions of how well they slept. That combination of long-term exposure data and objective sleep measurement is rare in cannabis research, and it gives the findings unusual weight.

The data came from the Coronary Artery Risk Development in Young Adults, or CARDIA, Study, a long-running, community-based investigation that began in 1985 and 1986 and follows Black and white adults across the United States. Among 1,266 participants analyzed, the researchers found that greater lifetime cannabis exposure was associated with poorer objective sleep quality. People with higher cumulative cannabis use spent a lower percentage of the night actually asleep, experienced more fragmented sleep, and spent more time awake after initially falling asleep. In other words, the more cannabis people had used over their lifetimes, the more their measured sleep bore the fingerprints of disruption.

Recent cannabis users showed similar patterns. Compared with people who never used cannabis, recent users were more likely to have lower sleep efficiency, greater sleep fragmentation, and longer periods of wakefulness during the night. They were also significantly more likely to sleep longer than eight hours per night — a detail that may sound like a benefit but can itself signal poor-quality, less restorative rest. Sleep that is long but fragmented and inefficient is not the same as sleep that is deep and continuous, and the monitors used in this study were able to distinguish between the two.

The perceptual gap emerged when researchers asked participants to rate their own sleep quality. Cannabis use showed no association with whether people felt they slept well or poorly. Users and non-users reported essentially similar subjective impressions of their rest, even as the wrist-worn devices told a different story. “This was one of the most interesting findings,” said corresponding author Dr. Thanh-Huyen T. Vu, research associate professor of preventive medicine (epidemiology) at Northwestern University Feinberg School of Medicine. “The wearable device detected more nighttime disruption among participants with long-term cannabis exposure, but the participants themselves generally did not report worse sleep.”

That mismatch matters for a simple reason: people decide whether a sleep aid is working based on how they feel, not on sensor data. If cannabis subtly fragments sleep architecture without producing a conscious sense of worse rest, users may continue to believe the drug is helping them while the measurable quality of their sleep quietly deteriorates. “This study challenges the common belief that cannabis helps people sleep better,” Vu said. “Our findings suggest cannabis may actually be associated with poorer sleep quality, even if people don’t perceive those changes.”

The study was not designed to determine whether cannabis directly causes sleep problems — an important caveat, since observational research of this kind can identify associations but cannot fully rule out other explanations. People who use cannabis may differ from non-users in ways the statistical models cannot completely capture. Still, the researchers adjusted for numerous factors known to affect sleep, including age, sex, race, cigarette smoking, alcohol use, physical activity, depression, chronic health conditions, and use of other substances. Cannabis use remained associated with poorer objectively measured sleep even after those adjustments, which the authors say provides some of the strongest evidence to date that long-term recreational cannabis use and better sleep quality may not be as closely aligned as commonly believed.

“Our data do not support the belief that cannabis is helpful as a sleep aid,” said senior author Mercedes R. Carnethon, chair of the department of preventive medicine at Feinberg. “As cannabis becomes increasingly available and accepted, it’s important to better understand its long-term associations with health behaviors such as sleep.” Her point speaks to a shifting landscape: as legalization spreads and cannabis products move from dispensaries into mainstream wellness culture, marketing claims about sleep benefits have proliferated, often ahead of the scientific evidence. A study of this scale and duration offers a rare longitudinal counterweight to anecdote.

The study does have limitations that the authors themselves acknowledge. The researchers did not distinguish between modes of cannabis consumption — smoking versus consuming edibles, for example — which could matter, since different delivery methods produce different chemical exposures and timelines. And because participants were followed over several decades, patterns of cannabis use likely changed over time, reflecting shifting products, potencies, and consumption habits across the generations of legalization. The study authors said this makes consumption mode an especially important question for future research.

For people seeking better sleep in the meantime, the study’s authors point to well-established strategies that do not involve cannabis. “Keep a regular bedtime, make your bedroom cool, dark and quiet, and avoid looking at phones and other screens right before bed,” said study co-author Kristen L. Knutson, associate professor of neurology (sleep medicine) and preventive medicine (epidemiology) at Feinberg. “It can also help to establish a calming routine before sleep, such as reading, meditating or taking a shower. If sleep problems persist, or if you’re a loud snorer, talk with your health care provider to rule out an underlying sleep disorder.” Those recommendations may lack the cultural cachet of a trendy sleep aid, but unlike cannabis, they come backed by decades of sleep science — and, as this study suggests, they do not carry the risk of disrupting the very rest they are meant to improve.

Subject of Research: Long-term associations between cannabis use and objectively measured sleep quality in middle-aged adults

Article Title: Think cannabis helps you sleep better? Think again.

Article References: Think cannabis helps you sleep better? Think again.. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cannabis, sleep quality, sleep aids, wearable sleep monitors, CARDIA study, JAMA Network Open, Northwestern University, epidemiology, sleep fragmentation, sleep efficiency, marijuana, public health

The stakes of this research extend well beyond academic curiosity. Gaming disorder, recognized by the World Health Organization in the International Classification of Diseases, and unspecified internet use disorder describe patterns of digital behavior in which gaming or online activity takes on a compulsive quality, crowding out other interests and continuing despite negative consequences. In adolescents, such patterns can lead to reduced mental and physical health as well as serious impairments in important areas of life, including school performance, family relationships, friendships, and leisure time. Excessive use of social media falls into the same problematic category. Against the backdrop of ongoing debates about how to protect the mental health of young people in the digital age, Lindenberg emphasizes that the question of effective interventions is highly relevant.

The policy landscape makes this urgency concrete. Alongside much-discussed regulatory measures such as age restrictions, there are parallel calls for approaches designed to empower young people to use video games and the Internet responsibly. These include prevention programs built on behavioral therapy principles and programs rooted in media education. Until now, however, robust empirical evidence comparing these two approaches head to head in real school settings has been scarce. Our research provides important empirical insights into which programs and content are particularly effective and which target groups benefit the most, Lindenberg notes, underscoring the practical orientation of the study.

To generate that evidence, the Heidelberg team designed a comparison between two interventions developed specifically for the school setting: PROTECTtraining, a behavioral therapy-based program, and PROTECTinfo, a media education program. The two interventions were deliberately engineered to be identical in duration and implementation effort, differing only in content. This methodological decision is what gives the study its analytical power. When two programs demand the same time, the same staffing, and the same logistical footprint, any difference in outcomes can be attributed to what the programs actually teach rather than to how they are delivered. In total, 1,793 students aged 11 to 18 took part in a four-week intervention consisting of four 90-minute sessions each.

Half of the participating adolescents completed PROTECTtraining, the behavioral therapy program. Its curriculum drew on well-established clinical techniques: among other elements, it explained the vicious cycle of addiction — the self-reinforcing loop in which short-term relief from negative emotions drives escalating use, which in turn deepens those emotions — and provided practical training in behavior change and emotion regulation. These components reflect the core machinery of cognitive behavioral therapy, which aims to interrupt maladaptive patterns by giving individuals concrete tools to recognize triggers, restructure their responses, and manage the emotional states that fuel compulsive behavior.

The second group participated in PROTECTinfo, the media education program, which covered a broad and socially relevant set of topics including media literacy, gaming, cyberbullying, and legal aspects of online behavior. This represents the approach most commonly deployed in schools: educating students about the digital world, its risks, and its norms, with the expectation that knowledge and awareness will translate into healthier habits. Both programs were delivered in the same format — four weekly sessions of 90 minutes over four weeks — ensuring that the comparison tested content, not delivery.

The researchers assessed participants’ online addiction behaviors and mental well-being at four points: at the beginning of the programs, at the end of the programs, and at follow-up intervals of four and twelve months. This longitudinal design allowed the team to distinguish short-term effects from durable ones, a critical distinction in prevention research where early gains often fade. In addition, the team conducted a separate analysis for adolescents who had been identified as having a comparatively high risk of addiction at the start of the study — a subgroup analysis that would prove decisive for interpreting the results.

The final survey, conducted one year after the programs began, revealed a nuanced picture. Among adolescents without a risk of addictive behavior, who constituted the majority of study participants, there was hardly any measurable effect on their symptoms. In other words, for the broad population of students who are not at risk, neither program produced substantial lasting change — a finding with significant implications for how prevention resources are allocated. In contrast, for adolescents at high risk of addiction, both interventions proved effective, but the behavioral therapy intervention was significantly more effective than its media education counterpart.

The magnitude of that difference is the study’s headline finding. In a direct comparison, the behavioral therapy program is 50 percent more effective against gaming disorder and other problematic online behaviors than the media education program, Prof. Lindenberg stresses. This effect size is substantial for a prevention intervention, particularly one delivered in a standard school setting with modest time investment. The result suggests that teaching at-risk adolescents the specific psychological mechanisms of addiction and equipping them with regulation and behavior-change skills does more to shift long-term outcomes than general education about media and its risks.

Beyond the head-to-head comparison, the Heidelberg researcher draws a broader structural conclusion from the data: targeted measures tailored to at-risk groups in the school setting achieve significantly better results and are more resource-efficient than prevention programs implemented on a broad scale. The pattern in the data supports this reading — the majority of students, those without addiction risk, showed hardly any measurable symptom change, while the high-risk subgroup, a smaller population, responded meaningfully to intervention, especially to the behavioral therapy approach. Concentrating effort on identifying and treating at-risk students, rather than delivering universal programs with diffuse effects, may therefore deliver more benefit per unit of investment.

The research was funded by the then Federal Ministry of Education and Research (BMBF) and the former Baden-Württemberg Ministry of Social Affairs and Integration, reflecting the policy significance attached to the question at both the national and state levels. The study, titled Cognitive Behavioral Therapy vs Media Literacy for Prevention of Gaming Disorder and Unspecified Internet Use Disorder, appeared in JAMA Network Open on 4 September 2026. For schools and health authorities weighing how to respond to growing concern about adolescent screen use, the message from Baden-Württemberg’s 44 secondary schools is clear: behavioral therapy-based prevention works, works best for those at highest risk, and outperforms media education by a wide margin when the two are measured against each other over a full year.

Subject of Research: School-based prevention of gaming disorder and problematic internet use in adolescents

Article Title: School-based prevention programs for gaming disorder and problematic online habits

Article References: School-based prevention programs for gaming disorder and problematic online habits. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gaming disorder, internet use disorder, adolescents, school-based prevention, cognitive behavioral therapy, media education, media literacy, randomized controlled trial, Heidelberg University, JAMA Network Open, Baden-Württemberg, mental health

The study, published in JAMA Network Open, evaluated a community-based behavioral intervention called H2GO!, which was designed to reduce children’s consumption of sugar-sweetened beverages and encourage them to drink more water. Over a 12-month follow-up period, children who participated in the intervention showed a significantly greater reduction in their body mass index z-score, or zBMI, compared with peers at comparison sites. The zBMI measure is a standard tool in pediatric research because it tracks BMI in growing children while accounting for age and sex, allowing researchers to assess whether a child’s weight status is improving or worsening relative to growth expectations rather than relying on raw BMI numbers alone.

Why focus on sugary drinks? Sugar-sweetened beverages, including regular sodas, fruit-flavored drinks, sports drinks, and energy drinks, are the largest source of added sugars in children’s diets. These liquid calories carry a particular metabolic liability: they do not produce the same sensation of fullness as solid food, so children who consume them tend not to compensate by eating less at their next meal. The result is an excess of total daily calories that can drive weight gain over time and raise the risk of developing type 2 diabetes, cardiovascular disease, and dental decay. Because beverage consumption patterns are established during formative life stages, and because intake remains stubbornly high among children and adolescents, sugary drinks represent an attractive and concrete target for prevention.

The intervention was delivered at Boys & Girls Club sites across Massachusetts, an organization that serves more than four million school-aged youth nationwide through academic, social, and leadership programming at roughly 5,500 locations. Trained club staff led 12 in-person group sessions with 437 children ages 8 to 13, each participating alongside a parent or caregiver. The six-week program, conducted in multiple waves between 2020 and 2025, blended interactive education with youth engagement: children took part in taste tests and sugar measurement demonstrations that made the hidden sugar content of common drinks visible and tangible, created print, music, and video projects explaining why drinking water mattered to them personally, and completed take-home activities with their parents to reinforce the message outside the club.

The study population reflected the communities that bear a disproportionate share of the childhood obesity burden. More than two-thirds of participating children qualified for free or reduced-price lunch, and more than half identified as Hispanic or Black. These communities are more likely to face structural barriers to maintaining a healthy weight, including economic constraints, neighborhood and environmental conditions that limit access to affordable healthy foods and safe opportunities for physical activity, and unequal access to preventive healthcare. The research team deliberately designed H2GO! to work within a trusted youth-based setting where children already develop everyday habits, rather than expecting families to seek out clinical services or navigate unfamiliar systems.

That design philosophy grew out of the team’s formative work with families and community partners. Corresponding author Dr. Monica Wang, associate professor of community health sciences at Boston University School of Public Health, who co-led the study with Selenne Alatorre, a senior research project manager at BUSPH at the time of the study, explained that asking families to change many dietary behaviors at once can quickly become overwhelming, particularly for those facing competing time and financial pressures. It is also difficult for a child, or an adult, to simply choose differently when sugary drinks are everywhere in the environment. The team focused instead on one simple, concrete change that did not require a costly or complicated overhaul of family life: drink fewer sugary beverages and more water.

The results at the 12-month follow-up were striking. At the start of the study, children consumed an average of 12 ounces of sugar-sweetened beverages and 24 ounces of water per day. By the end of the follow-up period, children who received the H2GO! intervention reported reducing their daily sugary drink intake by an average of 3.6 ounces while increasing daily water consumption by an average of 6.6 ounces. In exploratory analyses, nearly 30 percent of participating children shifted to a lower BMI category over the 12 months, compared with 18 percent of children at comparison sites. Among children who began the study with overweight, 44.4 percent of those in the intervention moved into the healthy-weight category, compared with 31.6 percent at comparison sites, and fewer progressed to obesity, at 5.6 percent versus 21.1 percent. Among children who began with obesity, 47.5 percent of those in H2GO! moved to a lower BMI category, compared with 36.7 percent at comparison sites.

Dr. Wang described one of the most striking findings as the ability to shift participants’ BMI in a healthier direction at a time when national childhood obesity trends were moving the opposite way, a signal that well-designed, community-based behavioral interventions can make a meaningful difference even against a difficult broader backdrop. The results also reaffirm that improving children’s health happens far beyond the pediatrician’s office. Community organizations, she noted, are critical partners in prevention because they are where children spend time, build relationships, and learn from one another. Embedding evidence-based health programming in settings children already trust may be one of the most practical routes to reaching families who face the greatest barriers to clinical care.

The trial builds on an earlier H2GO! pilot study conducted over six months at two Boys & Girls Club sites from 2016 to 2017, which also produced lower zBMI scores and reduced sugary drink intake among participants. The latest multi-site randomized controlled trial expanded the approach across the Commonwealth of Massachusetts, demonstrating that the community-tailored model is both effective and scalable. The intervention culminated in a community event where children showcased the work they had created and the lessons they had learned, reinforcing ownership of the health messages they had crafted themselves. The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases and coauthored by researchers at Boston University School of Public Health, Harvard T.H. Chan School of Public Health, Boston Medical Center, the University of Connecticut School of Social Work, the Massachusetts Alliance of Boys & Girls Clubs, and the University of Massachusetts T.H. Chan School of Medicine.

The researchers are careful to note the limitations of the work. Measurement differences and reliance on self-reported sugary beverage and water intake mean that more research is needed to understand whether additional factors may have contributed to the observed changes in children’s BMI trajectories. Future studies, the team says, should explore how this type of intervention could be delivered in other community settings and applied to other dietary behaviors, such as the consumption of ultra-processed foods. Still, the central message is an encouraging one for public health: large-scale policy and environmental changes remain essential, but communities do not have to wait for them to make progress. By giving children and families practical tools to make healthier choices within the environments they live in now, programs like H2GO! demonstrate that acknowledging structural barriers and strengthening the agency that families and communities already have can go hand in hand—and that sometimes the most powerful intervention is also the simplest one.

Subject of Research: A community-based behavioral intervention reducing sugar-sweetened beverage consumption and body mass index in school-aged children

Article Title: Afterschool-based intervention helps steer children toward healthier BMI scores

Article References: Afterschool-based intervention helps steer children toward healthier BMI scores. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: childhood obesity, sugar-sweetened beverages, BMI z-score, randomized controlled trial, afterschool programs, Boys & Girls Clubs, water consumption, behavioral intervention, public health, health equity, pediatric nutrition, JAMA Network Open

Second-generation antipsychotics, sometimes called atypical antipsychotics, were introduced in part because they promised a more favorable side-effect profile than the older first-generation drugs, which were notorious for causing movement disorders. Previous research had hinted that the second-generation class as a whole might carry a lower risk of hyponatremia than the first-generation agents. What remained unclear, however, was whether the risk differed meaningfully between individual drugs within the class. This distinction matters enormously in clinical practice. If all second-generation antipsychotics carried the same hyponatremia risk, clinicians could choose among them based on other considerations. But if the risk varies from one molecule to the next, that variation could become a decisive factor when prescribing for patients who are already vulnerable to sodium disturbances, such as older adults, people taking other medications that affect sodium levels, or those with underlying medical conditions.

Addressing this question, a research team led by Associate Professor Masakazu Hatano of the Department of Pharmacotherapeutics and Informatics at Fujita Health University School of Medicine in Japan, together with Dr. Takenao Koseki, Dr. Takeo Saito, and Dr. Shigeki Yamada, all affiliated with the same institution, carried out a two-stage comparative safety study. Their strategy combined two very different types of data, each with distinct strengths and weaknesses, to arrive at conclusions more robust than either source could provide alone. Hyponatremia is a recognized safety concern associated with antipsychotic use, but as Dr. Hatano explained, comparative evidence among individual second-generation antipsychotics has remained limited. The team therefore adopted a two-stage approach, first using a spontaneous reporting system to generate hypotheses about hyponatremia risk among individual drugs, and then using a claims database to evaluate the associations suggested by the first analysis.

The hypothesis-generating stage drew on the US Food and Drug Administration Adverse Event Reporting System, a vast pharmacovigilance repository that collects reports of suspected side effects from manufacturers, healthcare professionals, and patients. The researchers examined reports spanning from the fourth quarter of 1997 to the third quarter of 2023, an enormous window covering more than a quarter century of clinical use. In total, the analysis included 17,805,418 reports, of which 458,745 involved second-generation antipsychotic monotherapy, meaning patients taking a single antipsychotic rather than a combination. Using a statistical technique known as disproportionality analysis, which compares how often a given adverse event is reported for one drug relative to others, the team calculated reporting odds ratios for hyponatremia with olanzapine as the reference drug. Several antipsychotics showed lower reporting odds than olanzapine, and brexpiprazole and lurasidone showed the lowest reporting odds of all.

However, the researchers were careful to emphasize that these findings could only be considered hypothesis-generating rather than definitive. Spontaneous reporting systems suffer from a fundamental limitation: they provide no denominator information. In other words, while the database records how many adverse event reports mention a particular drug, it does not record how many people in total took that drug. Without knowing the size of the exposed population, it is impossible to calculate actual incidence or absolute risk. Reporting is also vulnerable to biases, including heightened attention to certain drugs, differences in how adverse events are recognized and attributed, and the passage of time as drugs gain or lose market share. A drug that is newly marketed or heavily scrutinized may generate more reports simply because clinicians are watching it more closely, not because it is genuinely more dangerous.

This is precisely why the second stage of the study was essential. The researchers turned to a Japanese hospital-based claims database covering April 2008 to April 2024, which allowed them to observe real patients over time rather than relying on voluntary reports. From this database, they identified 55,394 patients who were newly prescribed antipsychotics, had no recent antipsychotic use, and had no existing hyponatremia, ensuring that the analysis captured new-onset events rather than pre-existing conditions. Each patient was followed for up to 180 days after starting treatment, a window long enough to capture events plausibly related to the medication while limiting the influence of unrelated changes over time. During the follow-up period, hyponatremia occurred in 366 patients, representing 0.7 percent of the cohort, a figure that provides the kind of absolute risk context that spontaneous reporting data can never supply.

The critical analytical challenge in observational studies of this kind is confounding. Patients are not randomly assigned to antipsychotics; clinicians choose drugs based on patient characteristics, illness severity, prior treatment history, and anticipated tolerability. These same characteristics may independently influence hyponatremia risk. To address this, the researchers used statistical weighting methods to account for differences in baseline characteristics and other factors influencing risk, effectively creating balanced comparison groups. After adjustment, one finding stood out clearly: aripiprazole was associated with a significantly lower risk of hyponatremia than olanzapine. The other antipsychotics examined did not show significant differences compared with olanzapine once adjustment was applied, a notable contrast with the unadjusted signals from the reporting database, where several drugs had appeared more favorable.

These findings suggest that the risk of hyponatremia may differ among individual second-generation antipsychotics, Dr. Hatano clarified, adding that aripiprazole was associated with a lower risk than olanzapine in the adjusted analysis, which may help inform antipsychotic selection for patients at higher risk of hyponatremia. The result is pharmacologically plausible. Aripiprazole is a partial dopamine agonist with a distinctive receptor profile that sets it apart from most other second-generation agents, and olanzapine is known for broader receptor binding and a heavier metabolic and sedative burden. While the study was not designed to establish mechanism, the divergence between these two widely used drugs underscores that the second-generation label conceals real pharmacological heterogeneity with potential clinical consequences.

The researchers were candid about the limitations of their work. The study was observational, meaning it could identify associations but not prove causation. Residual confounding, the possibility that unmeasured differences between patient groups influenced the results, cannot be excluded, and differences in how hyponatremia was detected across treatment groups may also have shaped the findings. Laboratory monitoring practices, for example, may differ depending on the drug prescribed and the patient’s perceived risk, which could bias event ascertainment. The Japanese setting of the claims analysis raises questions about generalizability to other populations, and the 180-day follow-up window may not capture risks emerging over longer treatment periods. The authors also disclosed financial relationships with numerous pharmaceutical companies, which are documented in the published conflict of interest statement.

Despite these caveats, the study represents a valuable methodological template for drug safety research. By combining the breadth of a pharmacovigilance database with the clinical realism of claims data, the researchers generated and then tested hypotheses in a way that neither source could accomplish alone, providing complementary evidence for comparing drug safety while transparently acknowledging the limitations of each approach. For clinicians, the practical message is that hyponatremia risk deserves consideration when selecting among second-generation antipsychotics, particularly for patients with additional risk factors such as advanced age, thiazide diuretic use, or pre-existing sodium disturbances. For researchers, the findings highlight the need for further studies to elucidate the associations between individual second-generation antipsychotics and hyponatremia, ideally with designs capable of confirming mechanism and quantifying absolute risk across diverse populations. As antipsychotic prescribing continues to expand worldwide, studies of this kind bring precision to a class of drugs too often treated as interchangeable, moving psychiatric pharmacotherapy closer to genuinely individualized care.

Subject of Research: Comparative risk of hyponatremia among second-generation antipsychotics

Article Title: Hyponatremia risk may differ across second-generation antipsychotics

Article References: Hyponatremia risk may differ across second-generation antipsychotics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hyponatremia, second-generation antipsychotics, aripiprazole, olanzapine, pharmacovigilance, FAERS, claims database, drug safety, schizophrenia, bipolar disorder, JAMA Network Open, observational study